75853-60-0

Usage

Uses

Used in Cardiovascular Applications:
Dehydroevodiamine hydrochloride is used as a vasorelaxant agent for the treatment of cardiovascular diseases. Its vasorelaxant properties contribute to the relaxation of the aorta, which can help alleviate symptoms associated with these conditions.
Used in Neurodegenerative Applications:
Dehydroevodiamine hydrochloride is used as a neuroprotective agent for the potential treatment of neurodegenerative conditions. By inhibiting the production of neurotoxic nitric oxide, it may offer protection against the degeneration of neurons and could be beneficial in managing diseases like Alzheimer's.
Used in Alzheimer's Disease Therapy:
Dehydroevodiamine hydrochloride is considered as a potential therapeutic agent for Alzheimer's disease. It is used to prevent beta-amyloid-induced toxicity, which is a key factor in the progression of this neurodegenerative disorder. Further research is needed to confirm its efficacy and safety in this context.

Upstream product

• 17952-82-8 1,2,3,4-tetrahydronorharman-1-one 
• 85-91-6 Methyl N-methylanthranilate 
• 10328-92-4 N-Methylisatoic anhydride 
• 526-43-2 N²-2-methylaminobenzoyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-one 
• 118-92-3 anthranilic acid 
• 518-17-2 evodiamine 
• 6502-82-5 N_b-formyltryptamine 
• 32539-42-7 (2-(1H-indol-3-yl)ethyl)carbamic acid phenyl ester 
• 61-54-1 tryptamine 
• 118-48-9 isatoic anhydride 
• 4894-26-2 3,4-dihydro-β-carboline 
• 830-96-6 Indole-3-propionic acid 

Downstream Products

• 1238-43-3 13b-hydroxyevodiamine 

Relevant academic research and scientific papers

Investigation into the stability and reactivity of the pentacyclic alkaloid dehydroevodiamine and the benz-analog thereof

Limited synthetic approaches to obtain the biologically active alkaloid dehydroevodiamine (DHED) are known to date. Undesired demethylation in the most widely applied route was found to be a hampering side reaction for the benz-DHED derivative leading to a quinazolinone, which represents a benz-rutaecarpine derivative. For rutaecarpine, a related plant alkaloid, many different synthetic approaches have been described. Alternative reaction procedures to obtain DHED such as methylation of rutaecarpine and oxidation of evodiamine were investigated to make DHED more easily accessible and the latter method proved to be the most successful one. Furthermore, the remarkable equilibrium between the ring closed quinazolinium and the ring open form of the compounds was systematically investigated by UV-vis measurements. The ring open form and the quinazolinium salt, form the same species when incubated in buffer solution for 24 h. A better soluble form, i.e., 'hydroxyevodiamine', seems to represent the biologically active form that has not yet been described.

An expedient protecting-group-free total synthesis of (±)- dievodiamine

The first total synthesis of the Evodia rutaecarpa derived natural product dievodiamine is described. The convergent synthesis was performed without protecting groups, delivering a route that is short and high yielding and uses limited chromatography. Key

Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine

Derived from the structures of the alkaloids rutaecarpine and dehydroevodiamine (DHED), and the long-known acetylcholinesterase (AChE) inhibitor tacrine, respectively, novel compounds were synthesised, including: 13-methyl-5,8-dihydro-6H-isoquino[1,2-b]quinazolin-13-ium chloride (12), (8Z)-5,6-dihydro-8H-isoquino[1,2-b]quinazolin-8-imine (13), 5,8-dihydro-6H- isoquino[1,2-b]quinazoline (15a), 13-methyl-5,8-dihydro-6H-isoquino[1,2-b] quinazolin-13-ium chloride (16), 5,7,8,13-tetrahydroindolo [2′,3′:3, 4]pyrido[2,1-b]quinazoline (17), and N-(2-phenylethyl)-N-[(12Z)-7,8,9,10- tetrahydroazepino [2,1-b]quinazolin-12(6H)-ylidene]amine (20), respectively. In a first step to evaluate their possible applicability for antiamnesic therapy, the inhibition of AChE and butyrylcholinesterase (BChE) were determined: compounds 13, 15a, 17, and 20 are moderate or strong inhibitors of ChE, the latter two compounds show a 10-fold higher affinity to BChE. Compound 12 is a moderate inhibitor of AChE showing selectivity towards this enzyme. (Chemical presented)